These results were not confirmed by a large phase III, randomized study, and growing evidence suggests that patients with EGFR gene mutation‐positive NSCLC are prone to developing brain metastases, with the frequency ranging from 44% to 63%.15, 16. Here, EGFR is linked to non-small cell lung carcinoma.